                         SEQUENCE LISTING

<110>  INSERM Transfert
 
<120>  Compositions for treating CD5+HLA-DR+ B or T cell related 
       diseases

<130>  BET 10P0728

<150>  EP 09 305 434.4
<151>  2009-05-14

<160>  16    

<170>  PatentIn version 3.4

<210>  1
<211>  107
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 light chain

<400>  1

Asp Ile Gln Val Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ile Ser Leu Thr Cys Arg Thr Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Phe Gln Gln Lys Pro Asp Gly Thr Phe Lys Arg Leu Ile 
        35                  40                  45              


Tyr Ala Thr Ser Ser Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  2
<211>  118
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 heavy chain

<400>  2

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly 
            20                  25                  30          


Tyr Tyr Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Ile Ser Tyr Ser Gly Phe Thr Asn Tyr Lys Thr Ser Leu 
    50                  55                  60                  


Ile Asn Arg Ile Ser Ile Thr His Asp Thr Ser Glu Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Asn Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Gly Asp Arg Thr Gly Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  3
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 light chain CDR1 (L1)

<400>  3

Gln Asp Ile Ser Asn Tyr 
1               5       


<210>  4
<211>  3
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 light chain CDR2 (L2)

<400>  4

Ala Thr Ser 
1           


<210>  5
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 light chain CDR3 (L3)

<400>  5

Leu Gln Tyr Ala Ser Tyr Pro Phe Thr 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 heavy chain CDR1 (H1)

<400>  6

Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr 
1               5                   


<210>  7
<211>  7
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 heavy chain CDR2 (H2)

<400>  7

Ile Ser Tyr Ser Gly Phe Thr 
1               5           


<210>  8
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-CD5 heavy chain CDR3 (H3)

<400>  8

Ala Gly Asp Arg Thr Gly Ser Trp Phe Ala Tyr 
1               5                   10      


<210>  9
<211>  107
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR light chain

<400>  9

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Gly Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  10
<211>  118
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR heavy chain

<400>  10

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Val Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Ala Trp Ile Asn Thr Tyr Asn Gly Glu Pro Thr His Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Gly Asp Tyr Tyr Gly Tyr Glu Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Ser Val Thr Val Ser Ser 
        115             


<210>  11
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR light chain CDR1 (L1)

<400>  11

Gln Gly Ile Ser Asn Tyr 
1               5       


<210>  12
<211>  3
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR light chain CDR2 (L2)

<400>  12

Tyr Thr Ser 
1           


<210>  13
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR light chain CDR3 (L3)

<400>  13

Gln Gln Tyr Ser Lys Leu Pro Trp Thr 
1               5                   


<210>  14
<211>  8
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR heavy chain CDR1 (H1)

<400>  14

Gly Tyr Ile Phe Thr Asn Tyr Gly 
1               5               


<210>  15
<211>  8
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR heavy chain CDR2 (H2)

<400>  15

Ile Asn Thr Tyr Asn Gly Glu Pro 
1               5               


<210>  16
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  anti-HLA-DR heavy chain CDR3 (H3)

<400>  16

Ala Arg Gly Asp Tyr Tyr Gly Tyr Glu Asp Tyr 
1               5                   10      